Incidence of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and impact on patient outcome

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Bonnet, Maryline ^a   Baudin, Elisabeth ^a   Jani, Ilesh V ^b   Nunes, Elizabete ^c   Verhoustraten, François ^d   Calmy, Alexandra ^e   Bastos, Rui ^c   Bhatt, Nilesh B ^b   Michon, Christophe ^f  

^a EPICENTRE   (France)

^b INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

^c MAPUTO CENTRAL HOSPITAL   (Mozambique)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f Centre Hospitalier de la Region d'Annecy   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CORTICOSTEROID; COTRIMOXAZOLE; EFAVIRENZ; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; HEMOGLOBIN; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; PYRIDOXINE; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; BODY MASS; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; INFECTION RISK; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; MOZAMBIQUE; OPEN STUDY; OPPORTUNISTIC INFECTION; PARADOXICAL TUBERCULOSIS; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PREDICTION; PROBABILITY; PROSPECTIVE STUDY; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SMEAR; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; BODY MASS INDEX; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; MORTALITY; MOZAMBIQUE; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; TUBERCULOSIS;

EID: 84893171008     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084585     Document Type: Article

References (33)

1. Gupta A, Nadkarni G, Yang WT, Chandrasekhar A, Gupte N et al. (2011) Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLOS ONE 6: e28691. doi:10.1371/journal.pone.0028691. PubMed: 22220193.
2. Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD (2013) Prevalent and Incident Tuberculosis Are Independent Risk Factors for Mortality among Patients Accessing Antiretroviral Therapy in South Africa. PLOS ONE 8: e55824. doi:10.1371/journal.pone.0055824. PubMed: 23418463.
3. Lawn SD, Wood R (2011) Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis 204(Suppl): 1159-1167. doi:10.1093/infdis/jir411. PubMed: 21996698.
4. Straetemans M, Bierrenbach AL, Nagelkerke N, Glaziou P, van der Werf MJ (2010) The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLOS ONE 5: e15241. doi:10.1371/journal.pone.0015241. PubMed: 21209936.
5. Gengiah TN, Gray AL, Naidoo K, Karim QA (2011) Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opin Drug Saf 10: 559-574. PubMed: 21204737.
6. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C et al. (2011) Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 365: 1492-1501. doi:10.1056/NEJMoa1014181. PubMed: 22010915.
7. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C et al. (2011) Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 365: 1471-1481. doi:10.1056/NEJMoa1013911. PubMed: 22010913.
8. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S et al. (2011) Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 365: 1482-1491. doi:10.1056/NEJMoa1013607. PubMed: 22010914.
9. French MA, Price P, Stone SF (2004) Immune restoration disease after antiretroviral therapy. AIDS 18: 1615-1627. doi:10.1097/01.aids.0000131375. 21070.06. PubMed: 15280772.
10. Müller M, Wandel S, Colebunders R, Attia S, Furrer H et al. (2010) Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 10: 251-261. doi:10.1016/S1473-3099(10)70026-8. PubMed: 20334848.
11. Burman W, Weis S, Vernon A, Khan A, Benator D et al. (2007) Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 11: 1282-1289. PubMed: 18229435.
12. Lawn SD, Myer L, Bekker LG, Wood R (2007) Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 21: 335-341. doi:10.1097/QAD. 0b013e328011efac. PubMed: 17255740.
13. Meintjes G, Lawn SD, Scano F, Maartens G, French MA et al. (2008) Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 8: 516-523. doi:10.1016/S1473-3099(08)70184-1. PubMed: 18652998.
14. Bonnet M, Bhatt N, Baudin E, Silva C, Michon C et al. (2013) Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Lancet Infect Dis 13: 303-312. doi:10.1016/S1473-3099(13)70007-0. PubMed: 23433590.
15. WHO (2010) Treatment of tuberculosis: guidelines for national programs. World Health Organization: Geneva.
16. Eshun-Wilson I, Havers F, Nachega JB, Prozesky HW, Taljaard JJ et al. (2010) Evaluation of paradoxical TB-associated IRIS with the use of standardized case definitions for resource-limited settings. J Int Assoc Physicians AIDS Care (Chic) 9: 104-108. doi:10.1177/1545109710361537. PubMed: 20160249.
17. Haddow LJ, Moosa MY, Mosam A, Moodley P, Parboosing R et al. (2012) Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa. PLOS ONE 7: e40623. doi:10.1371/journal.pone.0040623. PubMed: 23152745.
18. Karmakar S, Sharma SK, Vashishtha R, Sharma A, Ranjan S, et al. (2011). Clinical characteristics of tuberculosis-associated immune reconstitution inflammatory syndrome in North Indian population of HIV/AIDS patients receiving HAART. Clin Dev Immunol 2011: 239021 doi:10.1155/2011/239021.
19. Naidoo K, Yende-Zuma N, Padayatchi N, Naidoo K, Jithoo N et al. (2012) The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med 157: 313-324. doi:10.7326/0003-4819-157-5-201209040-00004. PubMed: 22944873.
20. Worodria W, Menten J, Massinga-Loembe M, Mazakpwe D, Bagenda DM et al. (2012) Clinical spectrum, risk factors and outcome of immune reconstitution inflammatory syndrome in patients with tuberculosis-HIV coinfection. Antivir Ther 17: 841-848. doi:10.3851/IMP2108. PubMed: 22543224.
21. Worodria W, Massinga-Loembe M, Mazakpwe D, Luzinda K, Menten J et al. (2011) Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy. J Acquir Immune Defic Syndr 58: 32-37. doi:10.1097/QAI.0b013e3182255dc2. PubMed: 21654499.
22. Colebunders R, John L, Huyst V, Kambugu A, Scano F et al. (2006) Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int J Tuberc Lung Dis 10: 946-953. PubMed: 16964782.
23. Bastard M, Soulinphumy K, Phimmasone P, Saadani AH, Ciaffi L et al. (2013) Women experience a better long-term immune recovery and a better survival on HAART in Lao People's Democratic Republic. BMC Infect Dis 13: 27. doi:10.1186/1471-2334-13-27. PubMed: 23339377.
24. French MA (2012) Immune reconstitution inflammatory syndrome: immune restoration disease 20 years on. Med J Aust; 196: 318-321. doi:10.5694/mja12. 10089. PubMed: 22432669.
25. Dibyendu D, Sarkar RN, Phaujdar S, Bhattacharyya K, Pal HK (2011) Incidence and risk factors of immune reconstitution inflammatory syndrome in HIV-TB coinfected patients. Braz J Infect Dis 15: 553-559. doi:10.1016/S1413- 8670(11)70250-1. PubMed: 22218514.
26. Manosuthi W, Van TH, Mankatitham W, Lueangniyomkul A, Ananworanich J et al. (2009) Clinical case definition and manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 23: 2467-2471. doi:10.1097/QAD.0b013e32832f7b59. PubMed: 19898217.
27. Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K et al. (2010) Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 24: 2381-2390. PubMed: 20808204.
28. Meintjes G, Scriven J, Marais S (2012) Management of the immune reconstitution inflammatory syndrome. Curr HIV/AIDS Rep 9: 238-250. doi:10.1007/s11904-012-0129-5. PubMed: 22752438.
29. Wong EB, Omar T, Setlhako GJ, Osih R, Feldman C et al. (2012) Causes of death on antiretroviral therapy: a post-mortem study from South Africa. PLOS ONE 7: e47542. doi:10.1371/journal.pone.0047542. PubMed: 23094059.
30. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S (2006) Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 53: 357-363. doi:10.1016/j.jinf.2006.01.002. PubMed: 16487593.
31. Hoyo-Ulloa I, Belaunzarán-Zamudio PF, Crabtree-Ramirez B, Galindo-Fraga A, Pérez-Aguinaga ME et al. (2011) Impact of the immune reconstitution inflammatory syndrome (IRIS) on mortality and morbidity in HIV-infected patients in Mexico. Int J Infect Dis 15: e408-e414. doi:10.1016/j.ijid.2011.02.007. PubMed: 21493116.
32. Novak RM, Richardson JT, Buchacz K, Chmiel JS, Durham MD et al. (2012) Immune reconstitution inflammatory syndrome: incidence and implications for mortality. AIDS 26: 721-730. doi:10.1097/QAD.0b013e3283511e91. PubMed: 22233655.
33. Kumarasamy N, Venkatesh KK, Vignesh R, Devaleenal B, Poongulali S et al. (2013) Clinical outcomes among HIV/Tuberculosis-coinfected patients developing immune reconstitution inflammatory syndrome after HAART initiation in South India. J Int Assoc Provid AIDS Care 12: 28-31. doi:10.1177/1545109712457711. PubMed: 23011868.